Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepivacaine vs Articaine for IANB in Pulpitis
NCT03725579Phase 3Unknown
- Sponsor
- Cairo University
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of mepivacaine in irreversible pulpitis (2 arms), sponsored by Cairo University. Primary endpoint: Pain intensity measured by Numerical Rating Scale. Status: unknown.
02
Drugs
mepivacaine
03
Conditions
irreversible pulpitis
Beyond the preview
Go deeper on NCT03725579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725579.